Suarez-Almazor, Maria E.
Pundole, Xerxes
Abdel-Wahab, Noha
Johnson, Douglas B.
Gupta, Dipti
Glezerman, Ilya
Cooksley, Tim
Anderson, Ronald
Blidner, Ada
Choi, Jennifer
Dougan, Michael
Ginex, Pamela
Girotra, Monica
Shannon, Vickie R.
Rapoport, Bernardo L. http://orcid.org/0000-0001-7610-3653
Article History
Received: 24 April 2020
Accepted: 20 August 2020
First Online: 27 August 2020
Compliance with ethical standards
:
: AW, XP, AB, RA, JC, TC, PG, DG RAG, and VRS have no conflict of interest to declare. MD reports grants from Novartis, other (SAB) from Neoleukin Therapeutics, personal fees from Partner Therapeutics, personal fees from Tillotts Pharma, and grants from Genentech, outside the submitted work. MG reports consultant work with Bristol Myers Squibb (BMS), and AstraZeneca, outside the submitted work. IG reports other (Stock Ownership) from Pfizer Inc., and personal fees from CytomX Inc., outside the submitted work. DBJ reports other (advisory board) from Array Biopharma, grants and other (advisory board) from BMS, other (advisory board) from Jansen, grants from Incyte, other (advisory board) from Merck, and other (advisory board) from Novartis, outside the submitted work. In addition, DBJ has a patent co-inventor on use of CTLA-4 agonist for IAEs pending. BLR reports personal fees and other (advisory board) from Merck and Co.; grants, personal fees, and other (advisory board) from BMS; grants, personal fees, and other (advisory board) from Roche South Africa; and personal fees and other (advisory board) from AstraZeneca, during the conduct of the study. MSA reports personal fees from Gilead, grants from Pfizer, and personal fees from Abbvie, outside the submitted work.